AVN-397 is a 5-hydroxytryptamine subtype 6 receptor antagonist drug developed by Avineuro Pharmaceuticals Inc. that can potentially be used to treat Alzheimer's disease and general anxiety disorder (GAD).[1][2] Avineuro announced that it would start Phase II clinical trials in 2009, and those trials were ongoing as of 2012.[3][4][5]Phase II trials are now listed as Discontinued.[6][7]

References

  1. ^ Griebel, Guy; Holmes, Andrew (2013). "50 years of hurdles and hope in anxiolytic drug discovery". Nature Reviews Drug Discovery. 12 (9): 667–687. doi:10.1038/nrd4075. ISSN 1474-1776. PMC 4176700. PMID 23989795. S2CID 6531810.
  2. ^ "AVN 397 - AdisInsight". adisinsight.springer.com. Retrieved 2023-03-12.
  3. ^ "Avineuro Announces Beginning Of Phase II Clinical Studies Of AVN-397, Potent Small Molecule For Treatment Of Anxiety And Alzheimer's Disease". BioSpace. Retrieved 2023-03-12.
  4. ^ Froestl, W.; Pfeifer, A.; Muhs, A. (2014). "Cognitive enhancers (Nootropics). Part 3: drugs interacting with targets other than receptors or enzymes. Disease-modifying drugs. Update 2014". Journal of Alzheimer's Disease. 42 (4): 1079–1149. doi:10.3233/JAD-141206. PMID 25061058. S2CID 998047. Retrieved 2023-03-12.
  5. ^ Medicines in Development / Mental Illnesses / 2012 Report (PDF), archived (PDF) from the original on 9 Jul 2022
  6. ^ "Search for drugs | Therapeutic Target Database".
  7. ^ "Delving into the Latest Updates on AVN-397 with Synapse". synapse.patsnap.com. Retrieved 2025-03-08.


Allikas: https://en.wikipedia.org/wiki/AVN-397
No tags for this post.